These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31092464)

  • 41. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.
    Yamashita H; Nishio M; Kobayashi S; Ando Y; Sugiura H; Zhang Z; Hamaguchi M; Mita K; Fujii Y; Iwase H
    Breast Cancer Res; 2005; 7(5):R753-64. PubMed ID: 16168121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
    Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
    Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expression of Hypoxia-Inducible Factor 1α in Invasive Breast Cancer with Metastasis to Lymph Nodes: Correlation with Steroid Receptors, HER2 and EPO-R.
    Badowska-Kozakiewicz A; Sobol M; Patera J
    Adv Clin Exp Med; 2016; 25(4):741-50. PubMed ID: 27629849
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
    Falck AK; Fernö M; Bendahl PO; Rydén L
    World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inducing or Preventing Subsequent Malignancies for Breast Cancer Survivors? Double-edged Sword of Estrogen Receptor and Progesterone Receptor.
    Hu ZY; Xiao H; Xiao M; Tang Y; Sun J; Xie ZM; Ouyang Q
    Clin Breast Cancer; 2018 Oct; 18(5):e1149-e1163. PubMed ID: 29885789
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
    Todorovic-Rakovic N; Neskovic-Konstantinovic Z
    J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Receptor expression discrepancy between primary and metastatic breast cancer lesions.
    Karagöz Özen DS; Ozturk MA; Aydin Ö; Turna ZH; Ilvan S; Özgüroglu M
    Oncol Res Treat; 2014; 37(11):622-6. PubMed ID: 25427579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
    Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
    J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intratumoral Heterogeneity in Breast Cancer: A Comparison of Primary and Metastatic Breast Cancers.
    Shi YJ; Tsang JY; Ni YB; Tse GM
    Oncologist; 2017 Apr; 22(4):487-490. PubMed ID: 28341760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution.
    Watanabe J; Hayashi T; Tadokoro Y; Nishimura S; Takahashi K
    Breast Cancer Res Treat; 2017 Dec; 166(3):911-917. PubMed ID: 28852946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?
    Sighoko D; Liu J; Hou N; Gustafson P; Huo D
    Oncologist; 2014 Jun; 19(6):592-601. PubMed ID: 24807915
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.
    Qiao W; Jia Z; Liu H; Liu Q; Zhang T; Guo W; Li P; Deng M; Li S
    PLoS One; 2017; 12(10):e0186191. PubMed ID: 29016671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discordance of immunohistochemical markers between primary and recurrent or metastatic breast cancer: A retrospective analysis of 107 cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Medicine (Baltimore); 2020 Jun; 99(25):e20738. PubMed ID: 32569215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with Trastuzumab.
    McGuire A; Kalinina O; Holian E; Curran C; Malone CA; McLaughlin R; Lowery A; Brown JAL; Kerin MJ
    Breast Cancer Res Treat; 2017 Jul; 164(1):221-229. PubMed ID: 28378298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
    Takuwa H; Tsuji W; Shintaku M; Yotsumoto F
    BMC Cancer; 2018 Dec; 18(1):1282. PubMed ID: 30577860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.